We are thrilled to share news of our recent successful closing of a €1.2 million seed round. This will allow us to continue our development and bring our unique technology for the treatment of cartilage defects to the hands of surgeons in the near future. We are thankful to our investors for their belief in our solution and our vision of becoming the gold standard in cartilage repair and positively impacting the lives of patients around the world.
One of our portfolio companies, Altach (an NLC Venture), has secured a €1.2 million investment. This capital injection will help Altach enhance their work in developing treatments for cartilage injuries, which are a major cause of osteoarthritis. Big congratulations to the CEO of Altach, Tomir Kosowski, CTO and one of the inventors, David Browe, and the rest of the Altach team for achieving this important milestone! 🔬 𝐀𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲: Altach, which started at Trinity College Dublin in 2022, has created a new type of scaffold that mimics natural cartilage. This can help the body heal faster and more effectively than traditional methods. 🌍 𝐌𝐚𝐫𝐤𝐞𝐭 𝐢𝐦𝐩𝐚𝐜𝐭: With over 600,000 cartilage repair procedures each year in the US alone, and a market expected to grow to $5.9 billion by 2031, the impact of Altach's technology is significant. 📈 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐬𝐮𝐩𝐩𝐨𝐫𝐭: This round of funding includes contributions from Spark Crowdfunding, NLC’s Stepping Stone Fund, Castanjo B.V., and two angel investors. Want to learn more about the impact of Altach’s work? Read the full article on Silicon Republic. 👇🏼 #NLC #impactinvesting #healthtech https://lnkd.in/eC_gmsWe